In HER2-positive early BC patients, no significant difference was reported between obese and non-obese patients treated in the N9831 adjuvant trial, which compared anthracycline/taxane-based regimen versus its combination with trastuzumab, as the trend toward decreased disease-free survival observed in obese patients treated with chemotherapy alone was reverted by combining chemotherapy with trastuzumab [4]. Here, ERBB2 is linked to breast cancer.